Biovica International AB (publ) (STO:BIOVIC.B)
Sweden · Delayed Price · Currency is SEK 0.6320
-0.0060 (-0.94%)
Sep 3, 2025, 5:29 PM CET
Biovica International AB Company Description
Biovica International AB (publ), a biotech company, develops and commercializes novel blood-based biomarker assays that enhance the monitoring and predicting of cancer therapies in the European Union, United States of America, and internationally.
It primarily focuses on breast cancer. The company develops DiviTum TKa, a blood-based biomarker assay that measures thymidine kinase activity, which is correlated with cell proliferation.
It serves cancer institutes, pharmaceutical companies, and collaborative groups. The company was incorporated in 2008 and is headquartered in Uppsala, Sweden.
Biovica International AB (publ)
| Country | Sweden |
| Founded | 2008 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 27 |
| CEO | Anders Rylander |
Contact Details
Address: Dag Hammarskjölds väg 54B Uppsala, Uppsala County 752 37 Sweden | |
| Phone | 46 1 84 44 48 30 |
| Website | biovica.com |
Stock Details
| Ticker Symbol | BIOVIC.B |
| Exchange | Nasdaq Stockholm |
| Fiscal Year | May - April |
| Reporting Currency | SEK |
| ISIN Number | SE0008613731 |
| SIC Code | 2835 |
Key Executives
| Name | Position |
|---|---|
| Anders Rylander | President, Chief Executive Officer and Director |
| Anders Moren | Chief Financial Officer |
| Hanna Ritzén | Chief Operating Officer |
| Henrik Winther D.V.M., Ph.D. | Senior Vice President of Business Development |
| Hector Tamburini | Head of US Laboratory Operations, Regulatory and Quality |